意美止吐药使用说明

[Drug Name] (Aprepitant Capsules)

[Indications] Prevention of acute and delayed nausea and vomiting caused by chemotherapy. Used in combination with steroids and 5-HT3 receptor antagonists to prevent and control nausea and vomiting caused by chemotherapy.

[Usage and Dosage] Take 125 mg orally 1 hour before chemotherapy, and 80 mg in the morning on days 2 and 3. 40m is used to prevent vomiting 3 hours before anesthesia surgery.

[Ingredients] The main ingredient of this product is aprepitant.

【Character】White opaque hard capsule, printed with the words 461 and 80mg.

[Adverse Reactions] Common adverse reactions include anorexia, weakness, fatigue, constipation, diarrhea, nausea and vomiting, etc., with an incidence rate between 10% and 18%. Among them, the incidence rates of interruption, weakness, and fatigue were higher in the Italian-American group than in the control group. Some other adverse reactions with a smaller incidence include: redness, upper respiratory tract infection, tachycardia, weakness, pelvic pain, bone pain, pelvic pain, rash, hypokalemia, anxiety, etc. Bradycardia, disorientation, perforated duodenal ulcer, and Stevens-Johnson syndrome have also been reported.

【Taboo】Do not use this product if you are allergic to any ingredients in this product. This product should not be used simultaneously with pimozide, terfenadine, astemizole, and cisapride. Aprepitant can produce a dose-dependent inhibition of cytochrome P450 isoenzyme 3A4 (CYP3A4), which increases the plasma concentration of these drugs, which may cause serious or life-threatening adverse reactions.

[Precautions] This product is a dose-dependent CYP3A4 inhibitor and must be used with caution in patients with drugs that are mainly metabolized by CYP3A4; some chemotherapy drugs are metabolized by CYP3A4. The moderate inhibitory effect of aprepitant 125 mg/80 mg on CYP3A4 may increase the plasma concentrations of these concomitantly administered drugs. When this product is used concurrently with warfarin, the international normalized ratio (INR) of prothrombin time can be significantly reduced. Patients who require long-term treatment with warfarin should closely monitor their INR within two weeks of starting the 3-day dosing schedule of this product in each chemotherapy cycle, especially on days 7-10.

The above instructions are instructions. Please use the medicine correctly under the guidance of a doctor.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.